Document Detail


BluePort: a platform to study the eosinophilic response of mice to the bite of a vector of Leishmania parasites, Lutzomyia longipalpis sand flies.
MedLine Citation:
PMID:  21048957     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND: Visceral Leishmaniasis is a serious human disease transmitted, in the New World, by Lutzomyia longipalpis sand flies. Natural resistance to Leishmania transmission in residents of endemic areas has been attributed to the acquisition of immunity to sand fly salivary proteins. One theoretical way to accelerate the acquisition of this immunity is to increase the density of antigen-presenting cells at the sand fly bite site. Here we describe a novel tissue platform that can be used for this purpose.
METHODOLOGY/PRINCIPAL FINDINGS: BluePort is a well-vascularized and macrophage-rich compartment induced in the subcutaneous tissue of mice via injection of agarose beads covered with Cibacron blue. We describe the sequence of inflammatory events leading to its formation and how it can be used to study the dermal response to the bite of L. longipalpis sand flies. Results presented indicate that a shift in the inflammatory response, from neutrophilic to eosinophilic, is the main histopathological feature associated with the immunity acquired through repeated exposure to the bite of sand flies, and that the BluePort tissue compartment could be used to accelerate this process. In addition, changes observed inside the BluePort parenchyma indicate that it could be used to study complex immunobiological processes, and to develop ectopic secondary lymphoid structures.
CONCLUSIONS/SIGNIFICANCE: Understanding the characteristics of the dermal response to the bite of sand flies is a critical element of strategies to control leishmaniasis using vaccines that target salivary proteins. Finding that dermal eosinophilia is such a prominent component of the anti-salivary immunity induced by repeated exposure to sand fly bites raises one important consideration: how to avoid the immunological conflict derived from a protective Th2-driven immunity directed to sand fly saliva with a protective Th1-driven immunity directed to the parasite. The BluePort platform is an ideal tool to address experimentally this conundrum.
Authors:
J Santiago Mejia; Amanda L Toot-Zimmer; Patricia C Schultheiss; Barry J Beaty; Richard G Titus
Related Documents :
1908507 - The interaction between cd8+ cytotoxic t cells and leishmania-infected macrophages.
12654087 - Endemically exposed asymptomatic individuals show no increase in the specific leishmani...
20102417 - Evaluation of localized and systemic immune responses in cutaneous leishmaniasis caused...
19149777 - In situ immune responses to interstitial pneumonitis in human visceral leishmaniasis.
21991097 - Decrease of circulating dendritic cells in burn patients.
9814597 - Glucocorticoids induce a th2 response in vitro.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2010-10-27
Journal Detail:
Title:  PloS one     Volume:  5     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2010  
Date Detail:
Created Date:  2010-11-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e13546     Citation Subset:  IM    
Affiliation:
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America. jsmejia@colostate.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Grant Support
ID/Acronym/Agency:
AI 065784/AI/NIAID NIH HHS

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Flower development as an interplay between dynamical physical fields and genetic networks.
Next Document:  Maternal depressive symptoms not associated with reduced height in young children in a US prospectiv...